Centrifugal abdominal lipodystrophy
(Redirected from Lipodystrophia centrifugalis abdominalis infantalis)
Centrifugal Abdominal Lipodystrophy
Centrifugal Abdominal Lipodystrophy (CAL), also known as Lipoatrophia annularis or Lipoatrophia semicircularis, is a rare, benign condition characterized by the localized loss of subcutaneous fat tissue in the abdominal region. The condition is often associated with repetitive physical trauma or pressure to the affected area.
Etiology[edit | edit source]
The exact cause of CAL is unknown, but it is believed to be multifactorial. Some researchers suggest that it may be related to repetitive minor trauma or pressure to the abdominal wall, while others propose a possible hormonal or metabolic cause. Endocrine disorders, diabetes, and obesity have also been associated with the condition.
Clinical Presentation[edit | edit source]
Patients with CAL typically present with a semicircular or annular band of fat loss in the abdominal region. The affected area is often asymptomatic, but some patients may experience mild discomfort or pain. The condition does not typically affect the patient's overall health or lifespan.
Diagnosis[edit | edit source]
Diagnosis of CAL is primarily based on clinical examination and patient history. Imaging studies such as CT scans or MRI may be used to confirm the diagnosis and rule out other conditions.
Treatment[edit | edit source]
There is currently no specific treatment for CAL. Management of the condition primarily involves avoiding repetitive trauma or pressure to the affected area. In some cases, cosmetic surgery may be considered to improve the appearance of the affected area.
Epidemiology[edit | edit source]
CAL is a rare condition, with only a few hundred cases reported in the medical literature. It affects both men and women, but appears to be more common in women. The condition typically develops in adulthood, but cases in children have also been reported.
See Also[edit | edit source]
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD's Wellness Encyclopedia |
Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Kondreddy Naveen, Prab R. Tumpati, MD